<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        
        
        
        <link rel="shortcut icon" href="../../img/favicon.ico">
        <title>Rheumatoid arthritis - MediWiki</title>
        <link href="../../css/bootstrap.min.css" rel="stylesheet">
        <link href="../../css/font-awesome.min.css" rel="stylesheet">
        <link href="../../css/base.css" rel="stylesheet">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/color-brewer.min.css">
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
        <script>hljs.highlightAll();</script> 
    </head>

    <body>
        <div class="navbar fixed-top navbar-expand-lg navbar-dark bg-primary">
            <div class="container">
                <a class="navbar-brand" href="../..">MediWiki</a>
                <!-- Expander button -->
                <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#navbar-collapse">
                    <span class="navbar-toggler-icon"></span>
                </button>

                <!-- Expanded navigation -->
                <div id="navbar-collapse" class="navbar-collapse collapse">
                        <!-- Main navigation -->
                        <ul class="nav navbar-nav">
                            <li class="navitem">
                                <a href="../../Basic%20Clinical%20Sciences.html" class="nav-link">Basic Clinical Sciences</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Internal%20Medicine.html" class="nav-link">Internal Medicine</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Surgery.html" class="nav-link">Surgery</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Psychiatry.html" class="nav-link">Psychiatry</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Critical%20Care.html" class="nav-link">Critical Care</a>
                            </li>
                        </ul>

                    <ul class="nav navbar-nav ml-auto">
                        <li class="nav-item">
                            <a href="#" class="nav-link" data-toggle="modal" data-target="#mkdocs_search_modal">
                                <i class="fa fa-search"></i> Search
                            </a>
                        </li>
                            <li class="nav-item">
                                <a rel="prev" href="Pyknodysostosis.html" class="nav-link">
                                    <i class="fa fa-arrow-left"></i> Previous
                                </a>
                            </li>
                            <li class="nav-item">
                                <a rel="next" href="Sarcoidosis.html" class="nav-link">
                                    Next <i class="fa fa-arrow-right"></i>
                                </a>
                            </li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="container">
            <div class="row">
                    <div class="col-md-3"><div class="navbar-light navbar-expand-md bs-sidebar hidden-print affix" role="complementary">
    <div class="navbar-header">
        <button type="button" class="navbar-toggler collapsed" data-toggle="collapse" data-target="#toc-collapse" title="Table of Contents">
            <span class="fa fa-angle-down"></span>
        </button>
    </div>

    
    <div id="toc-collapse" class="navbar-collapse collapse card bg-secondary">
        <ul class="nav flex-column">
            
            <li class="nav-item" data-level="1"><a href="#rheumatoid-arthritis" class="nav-link">Rheumatoid arthritis</a>
              <ul class="nav flex-column">
            <li class="nav-item" data-level="2"><a href="#background" class="nav-link">Background</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#pathology" class="nav-link">Pathology</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#clinical-features" class="nav-link">Clinical features</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#differentials" class="nav-link">Differentials</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#diagnostic-criteria" class="nav-link">Diagnostic criteria</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#investigations" class="nav-link">Investigations</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#management" class="nav-link">Management</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#prognosis" class="nav-link">Prognosis</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#methotrexate-toxicities" class="nav-link">Methotrexate toxicities</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#tnf-inhibitor-therapy-adverse-effects" class="nav-link">TNF inhibitor therapy adverse effects</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#abatacept" class="nav-link">Abatacept</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#rituximab" class="nav-link">Rituximab</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#tocilizumab" class="nav-link">Tocilizumab</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#tofacitinib" class="nav-link">Tofacitinib</a>
              <ul class="nav flex-column">
              </ul>
            </li>
              </ul>
            </li>
        </ul>
    </div>
</div></div>
                    <div class="col-md-9" role="main">

<h1 id="rheumatoid-arthritis">Rheumatoid arthritis</h1>
<h2 id="background">Background</h2>
<ul>
<li>systemic disease affecting joints<ul>
<li>untreated or undertreated â†’ pain, disability, risk of death</li>
</ul>
</li>
<li>extra-articular effects<ul>
<li>lung, increased CVD risk</li>
</ul>
</li>
<li>early recognition and intervention improves functional outcomes</li>
<li>F:M = 3:1, onset 25-30 years</li>
</ul>
<h2 id="pathology">Pathology</h2>
<ul>
<li>HLA-DR1/4 associated disease, worsened by smoking, with chronic joint inflammation. Presents with early morning stiffness, and degenerative change on XR. Atlantoaxial instability and constitutional symptoms (Fatigue, weight loss, anaemia, fever) may also present.</li>
</ul>
<h2 id="clinical-features">Clinical features</h2>
<ul>
<li>symmetric synovitis, can start in 1-2 joints assymetrically<ul>
<li>small point involvement most common<ul>
<li>MCP and wrist involvement<ul>
<li>XR - erosions - progressive and severe disease (aim to avoid)</li>
</ul>
</li>
<li>cervical spine can occur; atlantoaxial instability or superior migration of dens</li>
</ul>
</li>
<li>lumbar spines spared</li>
</ul>
</li>
<li>extra-articular involvement<ul>
<li>scleritis</li>
<li>rheumatoid vasculitis of skin (finger tips)</li>
<li>nodulosis</li>
<li>interstitial lung diseases - mirrors IPF in terms of morbidity and mortality</li>
<li>increased risk of lymphoma - immune dysregulation</li>
<li>cardiovascular<ul>
<li>vasculitis</li>
<li>pericarditis</li>
<li>coronary artery disease</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="differentials">Differentials</h2>
<ul>
<li>Seronegative spondyloarthritis (Psoriatic arthrtisi, ankspon, reactive, IBD)</li>
<li>infection (viral, Lyme, septic)</li>
<li>SLE</li>
<li>PMR</li>
<li>Sarcoidosis</li>
<li>Crystalling disease (gout / pseudogout)</li>
<li>Vasculitis</li>
</ul>
<h2 id="diagnostic-criteria">Diagnostic criteria</h2>
<h2 id="investigations">Investigations</h2>
<ul>
<li>2010 classification criteria from ACR/EULAR for testing of RA<ul>
<li>patients with synovitis of at least one joint with no other explanation - after joint aspirate
<img alt="" src="../../figures/Pasted%20image%2020231025224235.png" /></li>
</ul>
</li>
</ul>
<h2 id="management">Management</h2>
<ul>
<li>Goal of therapy to start within 3 months of disease onset</li>
<li>Prior to initiating immunosuppressive therapy<ul>
<li>Labs baseline: LFT, EUC, FBC, HepB/C, TB testing</li>
<li>Vaccinations: Influenza, Pneumonia (PCV13, PPSV23)</li>
<li>Live vaccinations - most contraindicated on significant immunosuppression, exception being zoster<ul>
<li>give &gt;1/12 prior to initiating therapy</li>
<li>zoster safe to give in mild immunosuppression<ul>
<li>azathioprine (&lt;3mg/kg)</li>
<li>MTX (&lt;0.4mg/kg)</li>
<li>Prednisone (&lt;20mg/d)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Mx:<ol>
<li>NSAIDs best to start</li>
<li>DMARDs: Methotrexate or sulfasalazine or leflunomide </li>
<li>methotrexate is the preferred DMARD - decreases EA manifestation, changes natural history, improves QoL and survival<ul>
<li>if severe disease, initiate COMBINATION MTX + cDMARD â†’ establishes control faster</li>
</ul>
</li>
<li>if cannot tolerate MTX:<ul>
<li>leflunomide - MOA similar to MTX - daily PO, tolerated similar to MTX</li>
<li>sulfasalazine - slower onset, not typically used as single agent; used as part of triple therapy</li>
<li>hydroxychloroquine - antimalarial; milder agent, used in combination therapy; ocular toxicity risk</li>
<li>tofacitinib - synthetic DMARD</li>
</ul>
</li>
<li>if does not respond to MTX:<ul>
<li>combination DMARD + MTX</li>
<li>Biologics (TNFi, other)</li>
<li>combination biologic w/ MTX</li>
<li>combination conventional and synthetic DMARD</li>
<li>Triple therapy vs. MTX + TNFi â†’ no differences in outcomes at 2 years, but less radiographic progression<ul>
<li>MTX + SSZ + HCQ = MTX + Etanercept in efficacy</li>
</ul>
</li>
</ul>
</li>
<li>TNFa inhibitors (inflximab, etanerept)<ul>
<li>all have similar effect with 60-70% response rate</li>
<li>work in early AND late disease, but better clinical outcomes when used in early disease</li>
<li>stabilises radiographic progression</li>
<li>can be used as a monotherapy but better outcomes when used w/ cDMARD</li>
</ul>
</li>
<li>anti-B-cell therapy: Rituximab</li>
<li>Sx â†’ Tendon repair/construction, synovectomy, jt replacement, arthrodesis</li>
<li>Steroids - controversial regarding long term use<ul>
<li>low dose (5-7.5mg OD ) + DMARD/biologic is advocated, but possibly not necessary</li>
<li>SOME patients need low dose steroids</li>
<li>can help in controlling pain/disability and improve QoL</li>
</ul>
</li>
</ol>
</li>
<li>Stopping treatment after achieving remission<ul>
<li>vast majority of patients need to remain on drugs otherwise they can flare<ul>
<li>many who stop flare and struggle to get under control - discontinuation flare within 2-3 years</li>
</ul>
</li>
<li>however can consider LOWERED dose (but NOT withdrawing)</li>
</ul>
</li>
</ul>
<h2 id="prognosis">Prognosis</h2>
<ul>
<li>seropositive RA has increased mortality vs seronegative<ul>
<li>increased CVD risk may be responsible for this</li>
</ul>
</li>
<li>70% decreased risk of mortality in those taking methotrxate &gt; 1 year<ul>
<li>?treatment vs. ?antiinflammatory effect of methotrexate</li>
</ul>
</li>
<li>RA with interstitial lung disease has significant decline but not as bad as interstitial pulmonary fibrosis</li>
<li>delayed treatment (EARLY RA LEIDEN COHORT) assessed &gt; 12 weeks after symptoms â†’ less DMARD free remission and more XR progrssion over 6 years<ul>
<li>i.e. early initiation of therapy results in clinically improved symptoms</li>
</ul>
</li>
<li>when looking at XR progression, use of DMARDs reduced XR progression of disease<ul>
<li>i.e. early initiation and aggressive DMARDs improve PFS</li>
</ul>
</li>
<li>Poor prognosis<ul>
<li>functional limitation</li>
<li>extraarticular disease</li>
<li>RF positivity or anti-CCP</li>
<li>bone erosions radiographically</li>
</ul>
</li>
<li>Disease activity score 28 joints (DAS28), SDAI, CDAI, MD-HAQ, RAPID3</li>
<li>rapid3 - patient centred measure of function, pain and global status</li>
</ul>
<hr />
<h2 id="methotrexate-toxicities">Methotrexate toxicities</h2>
<ul>
<li>Gastrointestinal discomfort (most common)</li>
<li>liver enzyme abnormalities (role of fibroscan) - can lead to cirrhosis in rare cases</li>
<li>hematological - neutropenia</li>
<li>opportunistic infections</li>
<li>effect on reproduction - need to stop for 3/12 prior attempting conception</li>
<li>rare complications<ul>
<li>lung toxicity (&lt;1%)</li>
<li>nephrotoxicity</li>
<li>malignancy (lymphoma)</li>
</ul>
</li>
</ul>
<hr />
<h2 id="tnf-inhibitor-therapy-adverse-effects">TNF inhibitor therapy adverse effects</h2>
<ul>
<li>Cutaneous - injection site reactions, diffuse rashes</li>
<li>infections - sepsis, septic jts, pneumococcus, TB</li>
<li>Cardiac - worsening CHF in advanced cardiomyopathy</li>
<li>Neurologic - demyelination</li>
<li>Oncologic - risk of lymphoma (though might be due to RA baseline increased lymphoma risk)<ul>
<li>large cohort study demonstrated no clear evidence of increased association of lymphoma and TNFi</li>
<li>possible skin cancer association</li>
</ul>
</li>
<li>pancytopenia, aplasia</li>
<li>autoimune manifestation<ul>
<li>granulomatous pulmonary disease</li>
<li>vasculitis</li>
<li>SLE-type GN</li>
<li>Psoriasis</li>
</ul>
</li>
</ul>
<p>Absolute contraindications
- Heart failure : CHF III/IV
- active/latent TB
- active infection
- demylinating disease - MS/ optic neuritis
- Consider malignancy - speak with oncologist prior to initiating</p>
<hr />
<h2 id="abatacept">Abatacept</h2>
<p><img alt="" src="../../figures/Pasted%20image%2020231025230952.png" />
- blockade of costimulatory pathway between T-cell and macrophage after antigen presentation
- weekly injection or monthly infusion
    - similar anti-TNF risks, but less TB activation risk
    - used +/- MTX; typically AFTER TNF failure
- takes 1-3/12 for it to work
- possible reduced risk of infection v.s. TNF inhibitor</p>
<hr />
<h2 id="rituximab">Rituximab</h2>
<ul>
<li>B-cell depletion </li>
<li>works in ~50% of antiTNF failures</li>
<li>takes 2-4/12 for effect</li>
<li>2 infusions, given 1000mg vs. 500mg</li>
<li>mainly used in seropositive patients<ul>
<li>some seronegative patients can respond to this drug</li>
</ul>
</li>
</ul>
<p>Adverse effects - note in body for 6 months
- PML (JC Virus) - rare but possible; Hep B
- Rashes including psoriasis
- low WCC
- low IgG for long durations - not sure of significance
- need to check for HepB core IgM prior to starting RTX - can be reactivated - can cause catastrophic reactivation and liver failure</p>
<hr />
<h2 id="tocilizumab">Tocilizumab</h2>
<ul>
<li>mab against IL-6R</li>
<li>50% response rate in TNF failures</li>
<li>onset 1-2 months</li>
<li>improvements in CRP (due to IL6 blockade), QoL, fatigue</li>
</ul>
<p>Adverse effects
- infections
- GI perforations - avoid in patients with diverticulitis history
- lipid, leukocytes and liver test abnormalities â†’ need regular LFT monitoring</p>
<p><img alt="" src="../../figures/Pasted%20image%2020231025231330.png" />
- binds IL-6R; stops JAK-STAT3 signalling â†’ affects acute phase responses</p>
<hr />
<h2 id="tofacitinib">Tofacitinib</h2>
<ul>
<li>new oral synthetic DMARD against JAK1 and JAK3</li>
<li>Indication<ul>
<li>active moderate severe RA</li>
<li>inadequate response or intolerance to MTX</li>
</ul>
</li>
<li>used as monotherapy or +MTX</li>
<li>Combination tofacitinib (5mg BD) + MTX (15-25mg per week) similar in efficacy to MTX + TNFi and more efficacious than tofacitinib alone</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231025231924.png" /></p>
<p>Potential complications
- infections - opportunistic, HZV
- lipid abnormalities
- neutropenia
- anaemia
- GI perforation
- increased serum creatinine - ?significant unclear
- LFTs
- malignancy</p>
<hr />
<p><img alt="" src="../../figures/Pasted%20image%2020231025232447.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232454.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232501.png" />
- patients on MTX for first 1-2 years are at risk of MTX pneumonitis, but it is very very rare (&lt;1%)
    - pleurisy or pneumonitis most likely due to infection</p>
<p><img alt="" src="../../figures/Pasted%20image%2020231025232609.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232753.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232813.png" /></p>
<p><img alt="" src="../../figures/Pasted%20image%2020231025232857.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232924.png" />
<img alt="" src="../../figures/Pasted%20image%2020231025232952.png" /></p></div>
            </div>
        </div>

        <footer class="col-md-12">
            <hr>
                <p>Copyright &copy; 2021 Weber Liu</p>
            <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a>.</p>
        </footer>
        <script src="../../js/jquery-3.6.0.min.js"></script>
        <script src="../../js/bootstrap.min.js"></script>
        <script>
            var base_url = "../..",
                shortcuts = {"help": 191, "next": 78, "previous": 80, "search": 83};
        </script>
        <script src="../../js/base.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="../../search/main.js"></script>

        <div class="modal" id="mkdocs_search_modal" tabindex="-1" role="dialog" aria-labelledby="searchModalLabel" aria-hidden="true">
    <div class="modal-dialog modal-lg">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="searchModalLabel">Search</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
                <p>From here you can search these documents. Enter your search terms below.</p>
                <form>
                    <div class="form-group">
                        <input type="search" class="form-control" placeholder="Search..." id="mkdocs-search-query" title="Type search term here">
                    </div>
                </form>
                <div id="mkdocs-search-results" data-no-results-text="No results found"></div>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div><div class="modal" id="mkdocs_keyboard_modal" tabindex="-1" role="dialog" aria-labelledby="keyboardModalLabel" aria-hidden="true">
    <div class="modal-dialog">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="keyboardModalLabel">Keyboard Shortcuts</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
              <table class="table">
                <thead>
                  <tr>
                    <th style="width: 20%;">Keys</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="help shortcut"><kbd>?</kbd></td>
                    <td>Open this help</td>
                  </tr>
                  <tr>
                    <td class="next shortcut"><kbd>n</kbd></td>
                    <td>Next page</td>
                  </tr>
                  <tr>
                    <td class="prev shortcut"><kbd>p</kbd></td>
                    <td>Previous page</td>
                  </tr>
                  <tr>
                    <td class="search shortcut"><kbd>s</kbd></td>
                    <td>Search</td>
                  </tr>
                </tbody>
              </table>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div>

    </body>
</html>
